Atlas Trials

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Clinical trial NCT01881230 · COMPLETED

Trial details

NCT number
NCT01881230
Sponsor
Celgene
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Breast TumorBreast CancerCancer of the BreastEstrogen Receptor- Negative Breast CancerHER2- Negative Breast CancerProgesterone Receptor- Negative Breast CancerRecurrent Breast CancerStage IV Breast CancerTriple-negative Breast CancerTriple-negative Metastatic Breast CancerMetastatic Breast Cancer
Start date
2013-09-26
Primary completion
2016-10-28
Enrollment
191

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.